Full Breakdown
Cigna Stops Covering GLP-1 Weight-Loss Drugs for Its Employees
6/3/2026, 6:39:45 AM
Coverage Change Effective July 1, 2026
Cigna announced that its Group Medical Plan will no longer cover GLP-1 medications prescribed for weight loss, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, beginning July 1, 2026. The decision applies only to Cigna’s employee health plan; coverage for GLP-1s used to treat type 2 diabetes will remain unchanged. Employees currently using the drugs can obtain them by paying cash through manufacturer sites or the pharmacy network TrumpRx, but such payments will not count toward deductibles or out-of-pocket limits. Employees must transition to cash-pay options or alternative therapies by June 30.
Background & Context
GLP-1 agonists have become a dominant class of anti-obesity drugs, driven by clinical efficacy. In 2026, prices fell as Novo Nordisk launched a Wegovy pill and Lilly introduced an oral formulation, Foundayo, both starting at $149 per month for the lowest dose. More U.S. employers are limiting or dropping coverage for these high-cost treatments.
Key Companies and Alternative Therapies
The change directly affects drugs from two manufacturers: Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Cigna will continue covering older generic weight-loss agents—phentermine, diethylpropion, benzphetamine, and phendimetrazine—though they are less effective. Evernorth and Express Scripts will administer the revised benefits.
Data & Statistics
New GLP-1 formulations start at $149 per month for the lowest dose. Cigna’s workforce totals 67,700 employees (88 % U.S.-based). Employees on GLP-1s have until June 30, 2026 for a final prescription refill.
Official Statements & Responses
A Cigna spokesperson said the plan’s coverage was ended because GLP-1 options have become more widely available and the company wants to focus on a broader suite of weight-management resources. The spokesperson confirmed that coverage for GLP-1s prescribed for type 2 diabetes will remain unchanged. The change applies only to the employee health plan and does not affect Cigna’s commercial or Medicare Advantage products.
Implications for Employees and the Broader Market
Employees who continue GLP-1 therapy must purchase the medication out-of-pocket, with payments excluded from deductibles or out-of-pocket maximums. Early research shows discontinuation often leads to weight regain and a decline in benefits within two years. By reverting to generic agents, Cigna is shifting coverage to lower-cost alternatives, though the efficacy gap may affect employee health outcomes.
Conflicting Reports & Gaps
The source provides only Cigna’s perspective; no independent analyses or alternative viewpoints are offered. Data on how many employees currently use GLP-1s, or projected health effects of the coverage loss, are not disclosed.
Verbatim Quotes
> “As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss,” — Cigna spokesperson
What’s Next
Cigna will monitor employee uptake of cash-pay options and use of covered generic drugs. The insurer has not signaled further changes to employee health benefits beyond the July 1 implementation.
